BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Earnings Results, Beats Estimates By $0.25 EPS

BioMarin Pharmaceutical (NASDAQ:BMRN) issued its earnings results on Thursday. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25, FiscalAI reports. The company had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 6.50% and a net margin of 8.29%.The firm’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.44 EPS. BioMarin Pharmaceutical updated its FY 2026 guidance to 4.900-5.100 EPS.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• Second-quarter revenue rose 20% year over year to nearly $1 billion, supported by broad-based demand and the Amicus contribution. BioMarin raised its full-year revenue, VOXZOGO revenue, and non-GAAP EPS guidance.
• The Amicus integration is progressing ahead of expectations, with projected peak revenue of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI/OPFOLDA, plus approximately $220 million in annual cost synergies by 2028. Management expects meaningful EPS accretion beginning in 2027 and deleveraging roughly one year earlier than previously anticipated.
• VOXZOGO revenue increased 14% year over year, while treated children grew more than 20% globally despite a new U.S. competitor. Approximately 90% of U.S. patients remained on therapy, and BioMarin submitted a supplemental application for hypochondroplasia approval, potentially supporting a 2027 launch.
• BioMarin added BMN 820, an oral CCR2 inhibitor in Phase III development for focal segmental glomerulosclerosis, to its late-stage pipeline. The company also expects to pursue additional clinical-stage business-development opportunities over the next 12 to 18 months.
• Acquisition financing is increasing annual interest expense by approximately $200 million, or $50 million per quarter, while reduced cash balances are lowering interest income. These factors, along with higher operating expenses, contributed to lower year-over-year non-GAAP diluted EPS in the quarter.

BioMarin Pharmaceutical Stock Up 3.8%

Shares of BMRN traded up $2.35 during trading hours on Friday, hitting $63.81. 4,365,182 shares of the company were exchanged, compared to its average volume of 2,059,677. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. The company has a market cap of $12.33 billion, a PE ratio of 46.58, a PEG ratio of 0.46 and a beta of 0.24. The firm’s 50 day moving average is $58.06 and its 200-day moving average is $57.01. BioMarin Pharmaceutical has a 52 week low of $49.26 and a 52 week high of $66.28.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported second-quarter revenue of approximately $990 million, up 20% year over year and above the $932 million consensus estimate. Adjusted EPS of $1.20 also exceeded expectations of roughly $0.95-$0.96, providing a clear earnings catalyst despite being below the $1.44 reported in the prior-year quarter. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company raised its full-year 2026 non-GAAP EPS outlook to $4.90-$5.10, above the approximately $4.80 analyst consensus. Revenue guidance of about $3.9 billion was maintained around expectations, while stronger growth projections were provided for VOXZOGO. BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
• Positive Sentiment: Management said the additions of GALAFOLD and POMBILITI plus OPFOLDA from Amicus, along with expected cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion, and cash flow through the mid-2030s. BioMarin Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Morgan Stanley raised its price target from $119 to $124 and maintained an “overweight” rating, signaling substantial confidence in BioMarin’s growth and earnings outlook. Morgan Stanley analyst action
• Neutral Sentiment: HC Wainwright increased its price target from $50 to $60 but retained a “neutral” rating, offering a more cautious view of the stock’s valuation and upside. HC Wainwright analyst action

Institutional Investors Weigh In On BioMarin Pharmaceutical

Large investors have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC raised its position in shares of BioMarin Pharmaceutical by 33.0% during the second quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 1,102 shares during the last quarter. FORA Capital LLC bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $224,000. Prelude Capital Management LLC acquired a new stake in BioMarin Pharmaceutical during the third quarter worth about $288,000. NorthRock Partners LLC grew its position in BioMarin Pharmaceutical by 11.8% during the third quarter. NorthRock Partners LLC now owns 5,420 shares of the biotechnology company’s stock worth $294,000 after buying an additional 574 shares in the last quarter. Finally, Osaic Holdings Inc. increased its stake in BioMarin Pharmaceutical by 54.8% during the second quarter. Osaic Holdings Inc. now owns 5,064 shares of the biotechnology company’s stock valued at $283,000 after acquiring an additional 1,793 shares during the period. Institutional investors own 98.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BMRN. Sanford C. Bernstein lowered their price objective on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. HC Wainwright lifted their target price on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a research note on Friday. Bank of America decreased their target price on shares of BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. UBS Group restated a “neutral” rating on shares of BioMarin Pharmaceutical in a report on Tuesday, July 14th. Finally, Morgan Stanley upped their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.86.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.